<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099888</url>
  </required_header>
  <id_info>
    <org_study_id>PCIA 203/18</org_study_id>
    <nct_id>NCT04099888</nct_id>
  </id_info>
  <brief_title>PCI Treatment/Gemcitabine &amp; Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer</brief_title>
  <acronym>RELEASE</acronym>
  <official_title>A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PCI Biotech AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PCI Biotech AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and effectiveness of fimaporfin-induced photochemical
      internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin
      chemotherapy compared to gemcitabine/cisplatin alone, in patients with inoperable
      cholangiocarcinoma (CCA). Participants will be randomly assigned to one of the treatment
      groups and will receive study treatment for 6 months, followed by assessments every 3 months,
      as applicable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholangiocarcinoma (CCA) is an uncommon adenocarcinoma arising from cells lining the bile
      ducts. Standard treatment options for CCA include surgery, radiotherapy and chemotherapy,
      dependent upon if the CCA is intra- or extra-hepatic. Surgical removal of the tumor is the
      only potential cure, and CCA is very resistant to standard pharmaceutical drug treatment,
      though chemotherapy has some effect. Current chemotherapy uses cisplatin plus gemcitabine.
      Photochemical internalisation (PCI) is a novel technology, where photochemical reactions are
      used to enhance the effect of drugs by increasing their ability cross cell membranes to
      interact with their intended target. This study will assess the safety and effectiveness of
      fimaporfin-induced PCI of gemcitabine complemented by systemic gemcitabine/cisplatin
      chemotherapy compared to gemcitabine/cisplatin alone, in patients with inoperable CCA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>From date of randomisation to date of objective disease progression or death, whichever comes first (in months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>From date of randomisation to date of death from any cause (in months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Best response recorded from start of treatment until disease progression/recurrence (according to RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Proportion of patients with measurable disease at baseline who have at least one visit response with a CR (complete response) or PR (partial response) noted (according to RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>From first documented tumour response until first documented disease progression, or death in the absence of disease progression (in months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>At 6 months and 12 months</time_frame>
    <description>Proportion of patients with BOR of CR, PR or SD (stable disease) (according to RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor size</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Best overall percentage change in tumour size from baseline (in millimeters (mm))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional tumour-related events and biliary complications</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Frequency and severity of loco-regional tumour related events and biliary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)/Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number and proportion of patients with AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve (AUC)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>In Arm A patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>In Arm A patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>In Arm A patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (QoL)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>QoL assessment. Patients select one of four answers to 22 questions ranging from 1 (not at all) to 4 (very much). Lower total scores indicate a more favorable QoL perception than a higher score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>PCI treatment in conjunction with Standard of Care (SoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: Gemcitabine/cisplatin chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimaporfin and Gemcitabine</intervention_name>
    <description>PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m^2) and intraluminal laser light application. Up to 2 PCI treatments will be given.</description>
    <arm_group_label>PCI treatment in conjunction with Standard of Care (SoC)</arm_group_label>
    <other_name>PCI treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Cisplatin chemotherapy</intervention_name>
    <description>Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.</description>
    <arm_group_label>PCI treatment in conjunction with Standard of Care (SoC)</arm_group_label>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <other_name>Standard of care (SoC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Each patient must provide signed and witnessed written informed consent and agree to
             comply with study protocol requirements.

          -  Histopathologically/cytologically (C5) verified adenocarcinoma consistent with
             cholangiocarcinoma (CCA).

          -  CCA must be considered inoperable with respect to radical resection.

          -  CCA must present with at least 1 lesion (measurable and/or non-measurable but
             evaluable) that can be accurately assessed at baseline and is suitable for repeated
             evaluation.

          -  If metastatic, metastases must be limited to liver parenchyma only and/or restricted
             only to the local lymph nodes with peritoneal engagement locally within close
             proximity to the hepatoduodenal ligament.

          -  Must have biliary lesion causing bile obstruction that requires stenting and is
             accessible for PCI light treatment (ie, extrahepatic CCA [perihilar or distal] only).

          -  Must have adequate biliary drainage (either at least 50% of the liver volume, or at
             least 2 sectors) with no evidence of active uncontrolled infection (patients on
             antibiotics are eligible).

          -  Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Estimated life expectancy of at least 12 weeks.

        Exclusion Criteria:

          -  Patients who have previously received any anti-tumor (either local or systemic)
             treatment for CCA.

          -  Patients with severe visceral disease other than CCA.

          -  Patients with primary sclerosing cholangitis.

          -  Patients with porphyria or hypersensitivity to porphyrins.

          -  Patients with an active second primary cancer, defined as one with a disease-free
             interval of &lt;5 years before screening, with the exception of adequately treated basal
             cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, in-situ
             carcinoma of the uterine cervix, or prostate cancer that is controlled by hormone
             therapy (patients may continue hormone therapy while on study).

          -  Patients not able to undergo contrast-enhanced CT or MRI.

          -  Patients currently participating in any other interventional clinical trial.

          -  Planned surgery, endoscopic examination or dental treatment in the first 30 days after
             PCI treatment.

          -  Co-existing ophthalmic disease likely to require slit-lamp examination within the
             first 90 days after PCI treatment.

          -  Clinically significant and uncontrolled cardiac disease with the exception of extra
             systoles or minor conduction abnormalities and controlled and well-treated chronic
             atrial fibrillation.

          -  Known allergy or sensitivity to photosensitisers (active substance and/or any of the
             excipients); or chronic use of other photosensitising therapies.

          -  Known hypersensitivity to or contraindication to the use of gemcitabine (active
             substance and/or any of the excipients).

          -  Known hypersensitivity to or contraindication to the use of cisplatin (active
             substance and/or any of the excipients).

          -  Patients with ataxia telangiectasia.

          -  Patients with significant hearing impairment.

          -  Patients planning to have or who have recently had vaccination with a live vaccine.

          -  Patients concurrently receiving treatment with phenytoin.

          -  Male patients unwilling to use highly effective contraception or female patients of
             childbearing potential unwilling to use highly effective form of contraception.
             Patients must continue the use of contraception during PCI treatment and subsequent
             chemotherapy for at least 6 months thereafter.

          -  Women who are breastfeeding or who have a positive pregnancy test at baseline.

          -  Patients with inadequate bone marrow function (absolute neutrophil count &lt;1.5 x
             10^9/L; platelet count &lt;100 x 10^9/L; haemoglobin &lt;6 mmol/L [transfusion allowed]).

          -  Inadequate liver function despite satisfactory endoscopic or percutaneous biliary tree
             stenting (serum bilirubin persisting at &gt;2.5 x upper limit of normal for the
             institution; aspartate aminotransferase or alanine aminotransferase &gt;3.0 x upper limit
             of normal or &gt;5 x upper limit of normal if liver metastases are present; alkaline
             phosphatase levels &gt;5.0 x upper limit of normal).

          -  Inadequate renal function, as determined by local practice for patients on
             fractionated platinum-based chemotherapy. Patients with creatinine clearance &lt;45
             mL/min (in France: &lt;60 mL/min) must not be included.

        Other protocol-defined criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PCI Biotech</last_name>
    <role>Study Director</role>
    <affiliation>PCI Biotech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>If sites have contact information, please contact directly. If not</last_name>
    <phone>please email</phone>
    <email>ClinicalTrials@pcibiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site Name</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital, 1365C Clifton Road NE</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center, 5841 South Maryland Avenue</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala, Syöpätautien klinikka</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <state>Cedex 09</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <state>Cedex 9</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy, Département de gastro-entérologie</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf, I. Medizinische Klinik und Poliklinik (Gastroenterologie mit Sektionen Infektiologie und Tropenmediz)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LAKUMED Kliniken</name>
      <address>
        <city>Landshut</city>
        <zip>84036</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig KöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim Universitätsklinikum gGmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ludwig-Maximilians-Universität MünchenKlinik</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord, Medizinische Klinik 6 - (Schwerpunkte Gastroenterologie, Hepatologie, Endokrinologie)</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Modena Policlinico</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro - CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NTC 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna, P.O Bäckencancer, Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Ian</state>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If you are interested in participating at this location, enter facility name and NCT 04099888 in subject line of email</last_name>
      <email>ClinicalTrials@pcibiotech.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase II</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Amphinex-induced Photochemical Internalisation</keyword>
  <keyword>PCI</keyword>
  <keyword>Amphinex</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Inoperable</keyword>
  <keyword>CCA</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Bile duct cancer</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Extrahepatic</keyword>
  <keyword>Perihilar</keyword>
  <keyword>Distal</keyword>
  <keyword>Fimaporfin</keyword>
  <keyword>Pivotal</keyword>
  <keyword>RELEASE</keyword>
  <keyword>PDT</keyword>
  <keyword>FimaChem</keyword>
  <keyword>Klatskin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

